Episode 81: Mithril Medicine (Now Anthropic)
Send us Fan Mail In this episode of Petri Dish Perspectives, we explore Mithril Medicine, the one-person biotech that Anthropic just acquired and the story behind the man who built it. Cody Tranbarger spent six years posting anonymously on biotech X as “Professor Oak,” built a reputation in the crossover investing world without ever revealing his name, and then founded Mithril with Atlas Venture, one full-time employee (himself), and Claude running operations across 11 external laboratories. He called it "Pipeline-in-a-Person". We break down the science behind Mithril’s bispecific antibody program, a molecular clamp designed to bridge failing muscle fibers to the surrounding matrix in children with LAMA2-related congenital muscular dystrophy and alpha-dystroglycanopathy, two of the rarest and most devastating muscle diseases with no approved treatments. We get into the mouse data showing 2x grip strength gains, the six Claude errors that propagated into real lab experiments, and how a single April 2026 post triggered the conversations that led to an acquisition. We also zoom out to ask the bigger question: why is an AI safety company buying drug companies? We dig into Dario Amodei’s vision of AI curing most diseases within a decade, the Coefficient Bio acquisition that set the stage, and the conflict-of-interest questions the pharma industry hasn’t answered yet. This is a story about what happens when AI moves from tool to teammate to co-founder and what it means for the future of drug development. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #PetriDishPerspectives #MithrilMedicine #AIinDrugDiscovery #RareDisease #LAMA2 #PipelineInAPerson #Anthropic #BiotechNews #DrugDiscovery #LifeSciences #BiotechInnovation #AIBiotech #PharmaNews #HealthcareInnovation Support the show © 2026 The Perspective Bureau LLC. All rights reserved.
- Transcript
- Chapters